Redeye: Northbaze Group Q2 2023 - Positive stance despite sales contraction
Redeye maintains a positive view of Northbaze, even in the face of a substantial sales contraction. While the company proactively addresses the reduced demand, the prevailing macroeconomic challenges continue to impact Northbaze’s top and bottom-line performance. Despite a challenging quarter, Northbaze is steadfast in its pursuit of recuperating and upholding a 10% EBITDA margin in 2023. Our view on Northbaze remains unchanged, leading us to maintain our existing fair-value range and base case.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/